Similar articles

• Vigabatrin causes profound reduction in serum alanine transaminase activity.

  Ryan MF, Samy A, Young J. Ryan MF, et al. Ann Clin Biochem. 1996 May;33 ( Pt 3):257-8. doi: 10.1177/000456329603300314. Ann Clin Biochem. 1996. PMID: 8791991 Clinical Trial. No abstract available.
• Reduction of plasma alanine aminotransferase during vigabatrin treatment.

  Foletti GB, Delisle MC, Bachmann C. Foletti GB, et al. Epilepsia. 1995 Aug;36(8):804-9. doi: 10.1111/j.1528-1157.1995.tb01618.x. Epilepsia. 1995. PMID: 7635099
• Suppression of elevated alanine aminotransferase activity in liver disease by vigabatrin.

  Williams A, Sekaninova S, Coakley J. Williams A, et al. J Paediatr Child Health. 1998 Aug;34(4):395-7. doi: 10.1046/j.1440-1754.1998.00249.x. J Paediatr Child Health. 1998. PMID: 9727187
• Vigabatrin.

  Shields WD, Sankar R. Shields WD, et al. Semin Pediatr Neurol. 1997 Mar;4(1):43-50. doi: 10.1016/s1071-9091(97)80008-3. Semin Pediatr Neurol. 1997. PMID: 9097366 Review.
• Vigabatrin.

  Calli J, Farrington E. Calli J, et al. Pediatr Nurs. 1998 Jul-Aug;24(4):357-61. Pediatr Nurs. 1998. PMID: 9849270 Review. No abstract available.